行情

OCX

OCX

ONCOCYTE
NASDAQ

实时行情|Nasdaq Last Sale

3.700
-0.300
-7.50%
盘后: 3.760 +0.06 +1.62% 16:49 09/24 EDT
开盘
3.980
昨收
4.000
最高
4.000
最低
3.690
成交量
36.52万
成交额
--
52周最高
6.57
52周最低
1.200
市值
3.39亿
市盈率(TTM)
-10.3035
分时
5日
1月
3月
1年
5年
OncoCyte Corporation 普通股的收益有多糟糕？ |使用资本回报率
Benzinga Pro data, OncoCyte Corporation Common Stock (AMEX:OCX) reported Q2 sales of $2.03 million. Earnings fell to a loss of $13.57 million, resulting in a 19.44% decrease from last quarter.
Benzinga · 3天前
Oncocyte 宣布在欧洲肿瘤内科学会年会上口头报告其 DetermaIO™免疫治疗反应测试的新数据
Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response Trial Investigators found DetermaIO outperformed 80 other immune related signatures in TNBC IRVINE, Calif., Sept. 20, 2021 (GLO...
GlobeNewswire · 5天前
OncoCyte 表示试验数据显示 DetermaIO 作为免疫治疗反应的预测生物标志物的潜力
MT Newswires · 6天前
Oncocyte 举办两部分关键意见领袖活动系列
Part 1: Transplant Rejection Testing – Wednesday, September 22nd @ 1pmET Part 2: DetermaIO™ in Triple-Negative Breast Cancer – Tuesday, September 28th @ 1pmET IRVINE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precisio...
GlobeNewswire · 6天前
现代医疗保健机构将 Oncocyte 评为 2021 年医疗保健行业的最佳工作场所之一
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, announced toda...
GlobeNewswire · 09/16 12:00
BRIEF-Oncocyte to Present New Data on DetermaIO in Oral Presentation from Late-Breaking Abstract at ESMO 2021
reuters.com · 09/13 13:24
Oncocyte 将于 2021 年 9 月 20 日在 ESMO 的最新摘要的口头报告中提供有关 NeoTRIPaPDL1 试验确定性的新数据
Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment,
Benzinga · 09/13 12:08
Oncocyte 将参加第五届年度湖街资本市场最佳创意增长会议
IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, ...
GlobeNewswire · 09/07 20:05
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解OCX最新的财务预测，通过OCX每股收益，每股净资产，每股现金流等数据分析ONCOCYTE近期的经营情况，然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测OCX价格均价为9.00，最高价位11.00，最低价为7.00。
EPS
机构持股
总机构数: 112
机构持股: 5,949.31万
持股比例: 64.96%
总股本: 9,158.18万
类型机构数股数
增持
26
308.78万
建仓
14
82.54万
减持
34
133.35万
平仓
10
52.81万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.13%
制药与医学研究
-1.02%
高管信息
Non-Executive Chairman/Independent Director
Cavan Redmond
President/Chief Executive Officer/Director
Ronald Andrews
Chief Financial Officer
Mitchell Levine
Chief Accounting Officer/Vice President/Controller
Li Yu
Other
Douglas Ross
Other
Padma Sundar
Independent Director
Andrew Arno
Independent Director
Jennifer Carter
Independent Director
Melinda Griffith
Independent Director
Alfred Kingsley
Independent Director
Andrew Last
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
OCX 简况
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

微牛提供Oncocyte Corporation(NASDAQ-OCX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的OCX股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易OCX股票基本功能。